Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.65 |
| ▸ | KDR | P35968 | 19/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | AXL | P30530 | 1/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | FLT4 | P35916 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | FPR1 | P21462 | 1/20 | 0.53 |
| ▸ | FPR3 | P25089 | 1/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.53 |
| ▸ | SMO | Q99835 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101683 | 0.86 | MET (0.60) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL3457986 | 0.79 | MET (1.00) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL3117535 | 0.79 | MET (0.70) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL3570597 | 0.77 | MET (0.79) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL1132734 | 0.77 | MET (0.88) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL25129971 | 0.76 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| Hydrochloric Acid SCHEMBL1132605 | 0.76 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL15103820 | 0.76 | MET (0.75) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL3111179 | 0.75 | ALDH1A1 (0.45) | METAXL | |
| SCHEMBL1879429 | 0.75 | MET (0.85) | METKDRPDGFRAPDGFRBAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | MET 357/4885KDR 807/4885PDGFRA 1017/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | MET 357/4885KDR 807/4885PDGFRA 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.